Literature DB >> 17161223

Circulating leptin and adiponectin levels in patients with primary hyperparathyroidism.

Enrica Delfini1, Luigi Petramala, Chiara Caliumi, Darlo Cotesta, Giorgio De Toma, Giuseppe Cavallaro, Giuseppe Panzironi, Daniele Diacinti, Savatore Minisola, Emilio D' Erasmo, Gian Franco Mazzuoli, Claudio Letizia.   

Abstract

Primary hyperparathyroidism (PHPT) has been associated with high cardiovascular morbidity and mortality; its pathogenesis is not fully understood. Moreover, many metabolic abnormalities are frequently present in patients with PHPT. Several substances (such as leptin and adiponectin) are secreted from adipocytes, which may contribute to regulate energy homeostasis and the development of cardiovascular diseases. We examined the relationship between leptin and adiponectin levels and metabolic disorders in 67 newly diagnosed never-treated patients with PHPT and in 46 healthy subjects (HS). Twenty (29.8%) patients with PHPT presented a metabolic syndrome (as defined by Adult Treatment Panel III criteria). Serum leptin and adiponectin levels in HS were 6.28 +/- 3.3 ng/mL (range, 1.7-19.2 ng/mL) and 6.65 +/- 1.7 microg/mL (range, 3.72-10.86 microg/mL), respectively. In all patients with PHPT, the mean leptin levels (34.28 +/- 20.4 ng/mL) were significantly higher than those of HS (P < .01) and, in particular, in PHPT patients with metabolic syndrome (52.63 +/- 31.2 ng/mL) and positively correlated with body mass index, waist circumference, and cholesterol. The mean adiponectin level was significantly lower (4.34 +/- 3.5 mug/mL) only in PHPT patients with metabolic syndrome (P < .005) and negatively correlated with waist circumference and fasting glucose. We concluded that increased serum level of leptin and decreased serum level of adiponectin coexist in patients with PHPT and may represent a pathogenetic factor for cardiovascular disease in this condition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17161223     DOI: 10.1016/j.metabol.2006.08.019

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  15 in total

Review 1.  The intriguing connections of leptin to hyperparathyroidism.

Authors:  Stergios A Polyzos; Leonidas Duntas; Jens Bollerslev
Journal:  Endocrine       Date:  2017-07-20       Impact factor: 3.633

2.  Emerging data on cardiovascular risk in primary hyperparathyroidism.

Authors:  Jessica Pepe; Sara Piemonte; Cristiana Cipriani; Mirella Cilli; Salvatore Minisola
Journal:  Endocrine       Date:  2014-09-10       Impact factor: 3.633

3.  Adipokines and bone metabolism: an interplay to untangle.

Authors:  J Pepe; C Cipriani; M Cilli; L Colangelo; S Minisola
Journal:  J Endocrinol Invest       Date:  2016-09-17       Impact factor: 4.256

4.  Prevalence and characteristics of metabolic syndrome in primary hyperparathyroidism.

Authors:  F Tassone; L Gianotti; C Baffoni; F Cesario; G Magro; M Pellegrino; I Emmolo; M Maccario; G Borretta
Journal:  J Endocrinol Invest       Date:  2011-12-21       Impact factor: 4.256

5.  Role of growth factors on human parathyroid adenoma cell proliferation.

Authors:  Giuseppe Cavallaro; Alessandra Cucina; Pierpaolo Coluccia; Luigi Petramala; Dario Cotesta; Andrea Polistena; Laura Zinnamosca; Claudio Letizia; Lodovico Rosato; Antonino Cavallaro; Giorgio De Toma
Journal:  World J Surg       Date:  2010-01       Impact factor: 3.352

6.  Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms.

Authors:  M Procopio; M Barale; S Bertaina; S Sigrist; R Mazzetti; M Loiacono; G Mengozzi; E Ghigo; M Maccario
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

Review 7.  Magnesium metabolism in health and disease.

Authors:  Carlos G Musso
Journal:  Int Urol Nephrol       Date:  2009-03-10       Impact factor: 2.370

8.  Endothelial function and endothelial nitric oxide synthase intron 4a/b polymorphism in primary hyperparathyroidism.

Authors:  A Ekmekci; N Abaci; N Colak Ozbey; A Agayev; N Aksakal; H Oflaz; N Erginel-Unaltuna; Y Erbil
Journal:  J Endocrinol Invest       Date:  2009-07-02       Impact factor: 4.256

9.  Relation of leptin and adiponectin with cardiovascular risk factors, intact parathormone, and vitamin D levels in patients with primary hyperparathyroidism.

Authors:  Daniel Antonio de Luis; Gonzalo Diaz Soto; Rosa Conde; Olatz Izaola; Beatriz de la Fuente
Journal:  J Clin Lab Anal       Date:  2012-09       Impact factor: 2.352

Review 10.  Parathyroid hormone and the cardiovascular system.

Authors:  Lorraine A Fitzpatrick; John P Bilezikian; Shonni J Silverberg
Journal:  Curr Osteoporos Rep       Date:  2008-06       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.